Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Bayles

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Critical Reviews in Immunology|January 20, 2015
Plasma cell formation, secretion, and persistence: the short and the long of itIan Bayles, Christine Milcarek
Pharmacological Research|October 1, 2016
The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic disseminationCharles Marusak, Ian Bayles, Jun Ma, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 21, 2014
Transcription elongation factor ELL2 drives Ig secretory-specific mRNA production and the unfolded protein responseKyung Soo Park, Ian Bayles, Alec Szlachta-McGinn, et al.
Nature Communications|November 8, 2023
Temporal chromatin accessibility changes define transcriptional states essential for osteosarcoma metastasisW Dean Pontius, Ellen S Hong, Zachary J Faber, et al.
Elife|February 14, 2019
Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomesStevephen Hung, Alina Saiakhova, Zachary J Faber, et al.
The Journal of Clinical Investigation|September 10, 2019
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcomaIan Bayles, Malgorzata Krajewska, W Dean Pontius, et al.
Nature Medicine|April 11, 2018
Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competenceJames J Morrow, Ian Bayles, Alister P W Funnell, et al.
Nature Medicine|January 16, 2018
Positively selected enhancer elements endow osteosarcoma cells with metastatic competenceJames J Morrow, Ian Bayles, Alister P W Funnell, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Critical Reviews in Immunology|January 20, 2015
Plasma cell formation, secretion, and persistence: the short and the long of itIan Bayles, Christine Milcarek
Pharmacological Research|October 1, 2016
The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic disseminationCharles Marusak, Ian Bayles, Jun Ma, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 21, 2014
Transcription elongation factor ELL2 drives Ig secretory-specific mRNA production and the unfolded protein responseKyung Soo Park, Ian Bayles, Alec Szlachta-McGinn, et al.
Nature Communications|November 8, 2023
Temporal chromatin accessibility changes define transcriptional states essential for osteosarcoma metastasisW Dean Pontius, Ellen S Hong, Zachary J Faber, et al.
Elife|February 14, 2019
Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomesStevephen Hung, Alina Saiakhova, Zachary J Faber, et al.
The Journal of Clinical Investigation|September 10, 2019
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcomaIan Bayles, Malgorzata Krajewska, W Dean Pontius, et al.
Nature Medicine|April 11, 2018
Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competenceJames J Morrow, Ian Bayles, Alister P W Funnell, et al.
Nature Medicine|January 16, 2018
Positively selected enhancer elements endow osteosarcoma cells with metastatic competenceJames J Morrow, Ian Bayles, Alister P W Funnell, et al.
Pageof 1